Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Weill Cornell Medicine Qatar, Doha, Qatar.
J Cell Physiol. 2019 Jun;234(6):8286-8294. doi: 10.1002/jcp.27699. Epub 2018 Nov 11.
The global prevalence of Type 2 diabetes mellitus and its associated complications are growing rapidly. Although the role of hyperglycemia is well recognized in the pathophysiology of diabetic complications, its exact underlying mechanisms are not fully understood. In this regard, accumulating evidence suggests that the role of inflammation appears pivotal, with studies showing that most diabetic complications are associated with an inflammatory response. Several classes of antidiabetic agents have been introduced for controlling glycemia, with evidence that these pharmacological agents may have modulatory effects on inflammation beyond their glucose-lowering activity. Here we review the latest evidence on the anti-inflammatory effects of commonly used antidiabetic medications and discuss the relevance of these effects on preventing diabetic complications.
全球 2 型糖尿病及其相关并发症的患病率正在迅速增长。虽然高血糖在糖尿病并发症的病理生理学中作用已得到充分认识，但确切的潜在机制尚不完全清楚。在这方面，越来越多的证据表明炎症的作用至关重要，研究表明，大多数糖尿病并发症都与炎症反应有关。已经引入了几类抗糖尿病药物来控制血糖，有证据表明，这些药物除了降低血糖作用外，还可能对炎症具有调节作用。在这里，我们回顾了常用抗糖尿病药物的抗炎作用的最新证据，并讨论了这些作用在预防糖尿病并发症方面的相关性。
